Our Approach

Ardelyx develops:

  • Innovative, minimally-systemic, small molecule and polymeric therapeutics that work exclusively in the GI tract to treat GI and cardio-renal diseases.
  • We have developed a proprietary drug discovery and design platform enabling us, in a rapid and cost-efficient manner, to discover and design novel drug candidates

Targeted Therapeutic Areas

Ardelyx has established a unique approach to drug development with programs targeting gut transporters, receptors, and enzymes

Therapeutic Areas

About Ardelyx

Ardelyx was founded in 2007 by Dominique Charmot, Ph.D., Peter Schultz, Ph.D. and Jean Frechet, Ph.D., to discover, develop and commercialize innovative, minimally-systemic, small molecule and polymeric therapeutics that work exclusively in the gastrointestinal (GI) tract to treat GI and cardio-renal diseases. We have developed a proprietary drug discovery and design platform enabling us, in a rapid and cost-efficient manner, to discover and design novel drug candidates. Utilizing our platform, we discovered and designed our lead product candidate, tenapanor, which in preclinical and clinical studies has consistently demonstrated the ability to reduce the absorption of dietary sodium and phosphorus, both of which are key factors in the progression of kidney disease.

We are developing our lead product candidate, tenapanor, for the treatment of irritable bowel syndrome with constipation (IBS-C) and for the treatment of hyperphosphatemia in end stage renal disease (ESRD) patients on dialysis. We are also developing RDX022 for the treatment of high potassium, or hyperkalemia, in kidney and heart disease patients.

To enhance our proprietary drug discovery and design platform, we have developed a cell-culture system to simulate gut tissues called Ardelyx Primary Enterocyte and Colonocyte Culture System (APECCS). In addition to tenapanor, we are advancing our earlier stage discovery and lead development programs focused in GI and cardio-renal diseases.